Moon, Rebecca J. http://orcid.org/0000-0003-2334-2284
Reginster, Jean-Yves http://orcid.org/0000-0001-6290-752X
Al-Daghri, Nasser M. http://orcid.org/0000-0001-5472-1725
Thiyagarajan, Jotheeswaran A.
Beaudart, Charlotte http://orcid.org/0000-0002-0827-5303
Bruyère, Olivier http://orcid.org/0000-0003-4269-9393
Burlet, Nansa
Chandran, Manju
da Silva, Mario Coelho
Conaghan, Philip G. http://orcid.org/0000-0002-3478-5665
Dere, Willard H. http://orcid.org/0000-0001-9620-6940
Diez-Perez, Adolfo
Hadji, Peyman http://orcid.org/0000-0003-4787-3151
Halbout, Philippe
Hiligsmann, Mickaël http://orcid.org/0000-0003-4274-9258
Kanis, John A. http://orcid.org/0000-0002-3129-4326
McCloskey, Eugene V. http://orcid.org/0000-0003-0177-8140
Ormarsdottir, Sif
Prieto-Alhambra, Daniel
Radermecker, Régis P. http://orcid.org/0000-0002-2866-8171
Rizzoli, René http://orcid.org/0000-0002-1537-422X
Al-Saleh, Yousef http://orcid.org/0000-0002-5875-0950
Silverman, Stuart L.
Simon, Lee S. http://orcid.org/0000-0001-5673-807X
Thomasius, Friederike
van Staa, Tjeerd http://orcid.org/0000-0001-9363-742X
Laslop, Andrea
Cooper, Cyrus http://orcid.org/0000-0003-3510-0709
Harvey, Nicholas C. http://orcid.org/0000-0002-8194-2512
Article History
Received: 3 March 2023
Accepted: 28 April 2023
First Online: 23 June 2023
Declarations
:
: This narrative article contains no original data and thus issues of ethics, informed consent and patient confidentiality do not apply.
: RJM has received travel bursaries from Kyowa Kirin. OB has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Orifarm, Sanofi, UCB and Viatris. MC has received honoraria for speaking and chairing engagements from AMGEN, DKSH and Kyowa Kirin. PGC has received speakers bureaus or consultancies from AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Galapagos, GlaxoSmithKline, Grunenthal, Merck, Novartis, Pfizer, Stryker and UCB, outside the submitted work. WHD is on the board of Directors for BioMarin, Seres, Mersana and Metagenomi, Chief Advisor to CEO at Angitia and is a former employee and shareholder at Eli Lilly and Amgen. MH has research grants paid to his institution from Amgen, Radius Health, and consulting fees from UCB. EVM reports research support and/or personal fees from Amgen, Eli Lilly, Fresenius Kabi, ObsEva and UCB, outside the submitted work. SO has received consultancy fees from Merck and Pfizer not related to the current work or therapeutic field. RR has speaker bureau or advisory board for Abiogen, Naturex, Nestlé and ObsEva. YAS reports lecture honoraria from Amgen, Eli Lilly and SAJA. SLS has acted as a consultant for Radius and Amgen, received funding from Radius for clinical trial and received travel support from Radius and grant support from Amgen. LSS discloses associations with Astrazeneca, Pfizer, Rigel, Eupraxia, Biosplice, EMDSerono, Horizon, Direct, Lilly, Kaniska, Protalix, Chemomab, TLC, SpineThera, Kyoto, PPD, Galvani, Urica, Transcode, Boehringer Ingelheim, Bristol Myers Squibb, Priovant, Roivant, Ampio, Aura, Aurinia, GSK, Xalud, Neumentum, Neema, Amzell, Applied Bio, Aptinyx, Bexson, Bone Med, Bone Therapeutics, Cancer Prevention, Cerebral Therapeutics, Chemocentryx, Diffusion Bio, Elorac, Enalare, Foundry Therapeutics, Galapagos, Histogen, Gilead, Idera, Intravital, Ingel, Kiel Labs, Mesoblast, Mpathix, Minerva, Regenosine, Samus, Sana, StageBio, Theraly, Unity and Viridian. FT reports personal fees from Amgen, Eli Lilly, Fresenius, Stada and UCB outside the submitted work. CC reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. JYR, NMA, JAT, CB, OB, NB, MCD, WHD, ADP, PH, PH, JAK, DPA, RPR, SLS, TVS and AL report no conflicts of interest related to this work.